NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 18 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Focuses on Long-Term Opportunity as Market Dynamics Evolve
Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid…
-
QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Analytics Beyond Traditional Screening
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio…
-
QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) MyndRenew(TM) Earns TruShield Certification
BioAdaptives (OTC: BDPT) announced that MyndRenew(TM), the nighttime component of its MyndSystem(TM) cognitive health platform, has received TruShield Certified status, confirming compliance with…